viDA Therapeutics is a Vancouver, Canada–based biotechnology company focused on novel, small-molecule granzyme inhibitors. Its lead compound is being advanced as a treatment for chronic dermatological inflammatory conditions, and the company is developing a suite of additional granzyme inhibitors for multiple routes of administration. viDA completed a patent filing for a series of molecules targeting Granzyme B on March 29, 2013. The company raised capital in a financing round totaling $3.64M, including a $750K second tranche announced in April 2013. Proceeds are intended to fund continued preclinical investigation of the lead compound and ongoing discovery and development efforts. viDA is led by President and CEO Alistair Duncan.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2013